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ME and My Shadow
Everyone Exposed to Methyleugenol
Whether you intend to or not, chances are
you will consume approximately 6 micro-
grams of methyleugenol (ME) today,
according to a report in this month's issue
by Dana B. Barr and colleagues ofa study
designed to measure ME in human blood _
serum [EHP 108:323-328]. ME is a com-
pound that occurs naturally in a variety of
spices and herbs, including clove oil, nutmeg,
allspice, and walnuts. In both its natural and
synthetic forms, it is an FDA-approved addi-
tive, and it is widely used as a flavoring
agent in desserts, condiments, and ciga-
rettes, as an attractant in insecticides,
and as a fragrance in perfumes and soaps.
Because of its structural similarity to other
flavorants that are known to be carcinogenic
such as safrole and estragole, ME has
come under suspicion of carcino-
genicity. Recent research, some of
which was conducted by the
National Toxicology Program
at the NIEHS, has shown
clearly that ME causes can-
cer in laboratory rodents
and suggests that it may
be a human carcinogen as
well. To accurately evalu-
ate the level of risk asso-
ciatedwith acompound,
both toxicologic and
human exposure data are
required.
The investigators-col-
laborating teams from the
ational Center for Environmental






may well be carcino-
genic to humans.
and Prevention and from the NIEHS-
used extremely sophisticated tools and care-
fully planned methodologies to arrive at the
conclusion that low-level exposure to ME
is virtually ubiquitous in the U.S. adult 4
population. They analyzed serum sam-fl
ples from 206 adults who had partici-
pated in the Third National Health*
and Nutrition Examination Survey
(NHANES III), conducted between 1988 and 1994. With the U
sensitivity and accuracy afforded by isotope dilution gas chro-
matography-high resolution mass spectrometry, they detected ME
in 98% ofthe samples. They then used pertinent questionnaire data
from NHANES III to analyze the laboratory results for statistical
significance among a wide variety of variables. Unfortunately,
none ofthose demographic and lifestyle variables were statistically
significant markers ofME exposure. The fact that there were no
clear "smokingguns" correlating to ME exposure led the authors
to conclude that it comes from a variety of sources, including
air, water, and foods containing naturally occurring ME. They
also believe these findings are a good indicator of the preva-
lence and expected serum concentrations that are likely to be
encountered in the U.S. population.
So, like it or not, most adults in America are probably
exposed to this suspected carcinogen every day and probably
have no way of avoiding the compound altogether. Barr and
colleagues also point out that children are likely to have high-
er concentrations of ME, given their smaller size and the
nature ofsome ofthe identified commercial sources of
ME, such as candy, ice cream,
chewing gum, and other sweets.
,Therefore, they say, ME exposure
and risk assessment in children is a
rucial area inwhich to focus future studies.
The authors are cautious to draw no further
conclusions beyondwhat their datawarrant-that
the appropriate information is now in place to
allow more comprehensive assessment of the
risk associated with human exposure to ME.
However, it seems clear that the end result of
that assessment could be the eventual elimination of
ME from the commercial marketplace. That
would at least remove the possibility of ME
exposure from avoidable sources, substantially
reducing the overall prevalence ofthe compound
in the population and the level ofrisk it poses to
human health. -Ernie Hood
Smoking-induced Leukemia
How Much Is Benzeneto Blame?
Benzene, known to cause leukemia, is present in cigarette smoke.
However, although smokers are one-and-a-half to two times more
likely to develop leukemia than nonsmokers, the degree to which
the risk ofleukemia can be attributed to the low doses ofbenzene
in cigarette smoke is uncertain. Also uncertain is the validity oflin-
ear models ofdose-response with respect to benzene and leukemia,
particularly at doses lower than those encountered in the workplace
(and studied) in the past. Some scientists have been concerned that
linear models-which link an increase in benzene exposure to a
corresponding increase in disease-may overestimate the risk of
leukemia.
In this month's issue, Jeffrey E. Korte and colleagues from the
University of North Carolina at Chapel Hill compared published
eidemiological data to their own risk assessment predic-
tions to determine the proportion of all types of
leukemia and acute myeloid leukemia (AML) attribut-
able to benzene in cigarette smoke [EHP
108:333-339]. They used linear models and one qua-
dratic model to formulate their predictions, which
allowed them to test linear models' ability to accurately
predict occupational and nonoccupational risk from
benzene exposure. This may be important to the future
of setting exposure limits in facilities where benzene is
used.
The researchers determined the proportion of smoking-
induced leukemia deaths causedby benzenebyfollowing a five-
step process in which they calculated the lifetime leukemia risk
from smoking, determined the potency of benzene in causing
leukemia, estimated the benzene dose from smoking, character-
ized the low-dose risk of leukemia from benzene, and compared
the predicted lifetime risk of leukemia from benzene in cigarettes
with the observed risk due to smoking. The applied their calcula-
tions to light (20 cigarettes daily) and heavy (40 or more cigarettes
daily) smokers, with comparisons to those who never smoked.
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When applying linear models to these steps, the researchers calcu-
lated that benzene is responsible for 8-48% of all smoking-induced
leukemia deaths and 12-58% of smoking-induced AML deaths.
These results, the researchers say, are reasonable, compared to pub-
lished dataon the numbers ofsuch deaths. The quadratic modelyield-
ed far less plausible results, suggesting that less than 1% ofsmoking-
inducedleukemiadeaths are benzene related. Some studies have found
benzene to be most strongly associated with AML, but the chemical's
linktootherformsofthediseasehas notbeenruledout.
The studynot onlyprovides information on the quantitative con-
tribution ofbenzene to cancer deaths from cigarette smoking, it also
helps demonstrate the validity oflinear models in extrapolating to
low doses ofbenzene. Benzene is an important industrial chemical
used in making nylon, film developer, and solvents. Industrial work-
ers are exposed to benzene concentrations that are 10-100 times
greater than those encountered by smokers. For the past decade, the
Occupational Safety and Health Administration and the U.S.
Environmental Protection Agency have used linear models to set
workplace benzene standards and evaluate environmental risks,
respectively; both are reviewing that approach. The researchers point
out that their results, beingplausible predictions, contradict the theo-
retical argument that linear models may overestimate the low-dose
risk from benzene. The results also show that ifthere is a threshold
dose belowwhich benzene does not cause leukemia, it is considerably
lowerthan that received bysmokers.
The researchers caution, however, that benzene is not the only
leukemia-causing chemical in cigarette smoke. They note t;4.
1,3-butadiene, styrene, N-nitrosodi-n-butylamine, urethane, and
radioactive elements are also suspected of being leukemogenic.
Benzene, however, appears to cause a substantial proportion of the
leukemiadeaths inducedbysmoking. -Harvey Black
Getting On Our Nerves
The Long-Term EffectsofChlorpyrifos
In the United States, termite treatments with chlorpyrifos, awidely
used organophosphate pesticide, are currently applied about 20
million times peryear to houses and lawns, and 82% ofU.S. adults
have detectable levels ofthe chlorpyrifos metabolite known as TCP
in their urine. Like other organophosphates, chlorpyrifos exhibits
moderate acute toxicity, with symptoms that include diarrhea and
increased urination, perspiration, tearing of the eyes, and saliva-
tion. In addition, it readily inhibits the enzyme plasma
cholinesterase at lowdoses and red-blood-cell cholinesterase athigh
doses. Results of a study by Kyle Steenland of the National
Institute for Occupational Safety and Health and colleagues in this
month's issue give some suggestion ofdelayed neurological effects
from exposure to chlorpyrifos, particularly amongsubjectswith ahis-
toryofpoisoning [EHP108:293-300].
First marketed in 1965, chlorpyrifos came into rapidly increasing
use after chlordane was banned for termite applications in 1988.
Summarizing reports from poison control centers, the U.S.
Environmental Protection Agency has conduded that chlorpyrifos is
one of the leading causes of insecticide poisoning in the United
States: 4,000-5,000 cases of accidental chlorpyrifos exposure were
reported in 1993-1994. However, few epidemiological studies on
chlorpyrifos neurotoxicity have been conducted.
Accordingly, the authors conducted a study of 191 termiticide
applicators who had used chlorpyrifos for at least one year between
1987 and 1997 in a 12-county area ofNorth Carolina. The applica-
tors had worked with chlorpyrifos for an average of2.4 years, with an
average of 2.5 years spent working with other pesticides. Steenland
The cancer culprit. New research shows that benzene in cigarettes is
responsible for a significant proportion of deaths from leukemia and
acute myeloid leukemia.
and colleagues note that before 1988 some of these applicators had
used chlordane, so that compoundwas included in theiranalysis.
The test protocol included conducting interviews and taking
workhistories, as well as administering neurological tests. Among the
latter were a vibrotactile sensitivity test and an evaluation of
arm/hand tremor, manual dexterity, vision, smell identification, and
nerve conduction velocity. The scientists also performed clinical
examinations, which involved urine samples and buccal (inner cheek)
swabs, as well as a questionnaire to be completed with listings ofany
neurological symptoms. These induded trouble remembering during
the previous month, loss ofmusde strength, numbness or tingling in
toes, and lackofcoordination orloss ofbalance.
Theaverage urinaryTCP level for 65 recentlyexposed applicators
was 629.5 micrograms per liter, as compared with 4.5 micrograms
per liter for the general U.S. population. Few significant differences
between applicators and controls were found in arm/hand tremor,
vision, smell, nerve conduction velocity, or visuomotor or neuro-
behavioral skills. On the other hand, the exposed group did not per-
form as well as controls in the pegboard test (which involves putting
as manypegs into slots in aboard as possiblewithin afixed time peri-
od) and some postural sway tests. Exposed subjects also reported sig-
nificantly more memoryand emotional problems, fatigue, and loss of
musde strength. Although the authors did not find evidence ofthese
symptoms during their evaluation, they note that their quantitative
tests maynothave been adequate to detect them.
In general, Steenland and colleagues found few exposure-related
effects for most tests, induding the dinical examination. However,
the exposed subjects consistently reported more current psycho-
logical and physical symptoms than the nonexposed subjects. The
differences in symptoms were more marked for former rather than cur-
rent applicators, suggesting a long-term effect. However, these differ-
ences were generally not more apparent for those with longer exposure
tochlorpyrifos. Future studiesshouldconsider thetemporal sequence of
exposure and any self-reported symptoms. Although the North
Carolina study involved a large, well-defined target population, the
authors suggest that it may not be representative ofall exposed work-
ers and that caution should be exercised in generalizing its results.
-Julian Josephson
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